The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Matti Sällberg om året som kommer: ”Större intresse riktas mot Europa”

Nu nalkas vinterns ledigheter. Det vill Life Science Sweden uppmärksamma genom att ställa bakåt- och framåtblickande frågor till branschprofiler fram till jul. ...

Verigraft fick Arvid Carlsson-priset

Göteborgsbaserade Verigraft belönas med Arvid Carlsson Award 2025 för ”banbrytande framsteg inom regenerativ medicin”.

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

Ukraine war fuels rise of totally resistent bacteria

War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.

Marie Gårdmark: “What to expect from Trump’s second term?”

One may complain about the complex multinational system in EU, but it gives us some predictability that cannot be easily overturned by different member states p...

Life science trends 2025 – Neurology

New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-...

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

FDA plans to replace animal testing with AI – “Paradigm shift”

The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...

Quretech granted a European patent for a new type of antibiotic

The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.

A new scientific event in Gothenburg

Life Science Sweden is holding an event in Gothenburg for the first time.

ZEISS presents the "Quality Innovation Summit"

A global event on the future of quality assurance.

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

The Top 10 Challenges Facing Laboratories Today

Navigating the Laboratory Automation Landscape

How the Foreign Office will promote Swedish life science exports

The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...

Ny behandling för dödlig lungsjukdom – första på ett decennium

För första gången på över tio år har nu ett nytt läkemedel godkänts mot den svårbehandlade lungsjukdomen idiopatisk lungfibros, IPF.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

Bioscience – Groundbreaking Research & Diagnostics: Gothenburg (2026)